KRAS status versus EGFR status in lung cancer therapy;Détermination du statut KRAS associé au statut EGFR pour la prise en charge thérapeutique des cancers bronchiques.

Bulletin du cancer

Volumn 96 Suppl, Issue , 2009, Pages

  Lacroix, L ^a   Besse, B ^a   Bidart, J M ^a   Bosq, J ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAS PROTEIN;

DRUG ANTAGONISM; GENETIC MARKER; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; REVIEW;

DNA MUTATIONAL ANALYSIS; GENES, RAS; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

MLCS; MLOWN;

EID: 75549091465     PISSN: None     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0999     Document Type: Review

References (61)